Naval Daver Selected Research

magrolimab

11/2022	Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia.
5/2021	Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Naval Daver Research Topics

Disease

114	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2022 - 04/2012
46	Neoplasms (Cancer) 10/2022 - 01/2013
31	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 05/2022 - 03/2013
30	Leukemia 01/2022 - 06/2013
17	Primary Myelofibrosis (Myelosclerosis) 12/2021 - 01/2013
16	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022 - 05/2015
15	Philadelphia Chromosome 01/2022 - 02/2015
15	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 06/2013
10	Infections 01/2022 - 11/2015
9	Residual Neoplasm 01/2021 - 06/2016
7	Acute Promyelocytic Leukemia 01/2022 - 05/2015
7	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 04/2015
6	Exanthema (Rash) 01/2021 - 11/2015
5	Anemia 01/2022 - 11/2013
5	Thrombocytopenia (Thrombopenia) 01/2022 - 01/2018
4	Bites and Stings (Sting) 01/2021 - 01/2017
4	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2021 - 01/2018
4	Blast Crisis (Blast Phase) 01/2021 - 12/2017
4	Pathologic Complete Response 01/2019 - 05/2015
3	Lymphoma (Lymphomas) 01/2022 - 05/2015
3	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 01/2018
3	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2021 - 04/2014
3	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 01/2021 - 01/2017
3	Hypertension (High Blood Pressure) 12/2020 - 11/2015
3	Hemorrhage 12/2018 - 01/2015
3	Mucositis 10/2017 - 06/2015
3	Multiple Myeloma 10/2017 - 02/2015
3	Splenomegaly 01/2017 - 10/2014
2	Leukocytosis (Pleocytosis) 01/2022 - 01/2017
2	Pneumonia (Pneumonitis) 01/2022 - 01/2020
2	Disease Progression 12/2021 - 01/2021
2	Febrile Neutropenia 08/2021 - 01/2018

Drug/Important Bio-Agent (IBA)

20	venetoclaxIBA 05/2022 - 01/2018
19	Azacitidine (5 Azacytidine)FDA Link 01/2022 - 06/2013
16	Tyrosine Kinase InhibitorsIBA 01/2022 - 02/2015
14	Immune Checkpoint InhibitorsIBA 01/2022 - 10/2016
13	Cytarabine (Cytosar-U)FDA LinkGeneric 05/2022 - 11/2013
9	Decitabine FDA Link 01/2022 - 02/2015
8	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2017
8	ruxolitinibIBA 01/2021 - 02/2015
7	NivolumabIBA 01/2022 - 01/2017
7	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 08/2021 - 11/2013
7	ponatinibIBA 01/2021 - 09/2015
7	Sorafenib (BAY 43-9006)FDA Link 11/2020 - 06/2013
6	AntibodiesIBA 01/2022 - 10/2016
6	Pharmaceutical PreparationsIBA 01/2022 - 09/2015
6	Core Binding Factors (Core-Binding Factor)IBA 01/2022 - 11/2015
6	Vincristine (Oncovin)FDA LinkGeneric 01/2021 - 02/2015
6	fms-Like Tyrosine Kinase 3IBA 01/2021 - 08/2012
6	Dasatinib (BMS 354825)FDA Link 01/2021 - 03/2016
5	Lenalidomide (CC 5013)FDA Link 10/2022 - 01/2015
5	Chimeric Antigen ReceptorsIBA 01/2022 - 02/2017
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 05/2015
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2018
5	AntigensIBA 01/2021 - 05/2016
5	Monoclonal AntibodiesIBA 01/2021 - 06/2013
5	Clofarabine (Clolar)FDA Link 01/2021 - 06/2013
5	Arsenic Trioxide (Trisenox)FDA Link 01/2019 - 05/2015
4	CreatinineIBA 01/2022 - 12/2018
4	CytokinesIBA 12/2021 - 01/2017
4	Biological ProductsIBA 01/2021 - 09/2013
4	Imatinib Mesylate (Gleevec)FDA Link 01/2020 - 05/2015
4	Gemtuzumab (Mylotarg)FDA Link 01/2020 - 01/2017
4	DNA (Deoxyribonucleic Acid)IBA 07/2019 - 02/2015
4	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2019 - 05/2015
4	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2019 - 08/2013
3	AnthracyclinesIBA 05/2022 - 01/2020
3	Cladribine FDA LinkGeneric 08/2021 - 01/2014
3	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2021 - 02/2017
3	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 02/2015
3	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 01/2017
3	SteroidsIBA 01/2021 - 06/2017
3	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2021 - 01/2013
3	Inotuzumab OzogamicinIBA 01/2021 - 01/2018
3	midostaurinIBA 11/2019 - 04/2015
3	blinatumomabIBA 01/2019 - 12/2017
3	BilirubinIBA 12/2018 - 02/2015
3	Transaminases (Aminotransferases)IBA 12/2018 - 02/2015
3	Prednisone (Sone)FDA LinkGeneric 12/2018 - 09/2014
3	pomalidomideIBA 10/2017 - 11/2013
3	Methotrexate (Mexate)FDA LinkGeneric 02/2017 - 02/2015
3	Hemoglobins (Hemoglobin)IBA 01/2017 - 09/2014
3	Rituximab (Mabthera)FDA Link 02/2015 - 02/2013
2	magrolimabIBA 11/2022 - 05/2021
2	purineIBA 05/2022 - 02/2013
2	IpilimumabIBA 01/2022 - 01/2017
2	cyclopropapyrroloindoleIBA 01/2022 - 01/2020
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 08/2015
2	gilteritinibIBA 01/2022 - 12/2021
2	Alanine Transaminase (SGPT)IBA 08/2021 - 11/2015
2	Agammaglobulinaemia Tyrosine KinaseIBA 01/2021 - 05/2015

Therapy/Procedure

85	Therapeutics 10/2022 - 01/2013
42	Drug Therapy (Chemotherapy) 05/2022 - 08/2013
12	Stem Cell Transplantation 10/2021 - 03/2013
8	Immunotherapy 01/2022 - 06/2013
8	Induction Chemotherapy 01/2022 - 08/2012
4	Hematopoietic Stem Cell Transplantation 01/2021 - 03/2013
3	Radiotherapy 10/2022 - 10/2014
3	Transplantation 01/2021 - 12/2019
3	Salvage Therapy 01/2021 - 01/2020